These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 2478982)

  • 1. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
    Munsif AN; Saksena S
    Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias.
    Saksena S; Klein GJ; Kowey PR; Calvo RA; Boccadamo R; Brown JE; Sharma AD; Gadhoke A; Olukotun AY
    Am J Cardiol; 1987 Feb; 59(4):307-12. PubMed ID: 3812280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias.
    Dorian P; Echt DS; Mead RH; Lee JT; Lebsack CS; Winkle RA
    Am Heart J; 1986 Aug; 112(2):327-33. PubMed ID: 3526852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta blockers in combination with class I antiarrhythmic agents.
    Deedwania PC; Olukotun AY; Kupersmith J; Jenkins P; Golden P
    Am J Cardiol; 1987 Aug; 60(6):21D-26D. PubMed ID: 2442991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
    Kus T; Costi P; Dubuc M; Shenasa M
    Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
    Wichter T; Borggrefe M; Haverkamp W; Chen X; Breithardt G
    Circulation; 1992 Jul; 86(1):29-37. PubMed ID: 1617780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
    Toivonen L; Kadish A; Morady F
    Circulation; 1991 Jul; 84(1):101-8. PubMed ID: 1905591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of propranolol added to a type I antiarrhythmic agent for sustained ventricular tachycardia secondary to coronary artery disease.
    Friehling TD; Lipshutz H; Marinchak RA; Stohler JL; Kowey PR
    Am J Cardiol; 1990 Jun; 65(20):1328-33. PubMed ID: 2343820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease.
    Khalighi K; Peters RW; Feliciano Z; Shorofsky SR; Gold MR
    Am J Cardiol; 1997 Sep; 80(5):591-4. PubMed ID: 9294987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
    Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
    Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation.
    Miura DS; Wynn J; Torres V; Laux B; Keefe D; Somberg JC
    Am Heart J; 1986 Apr; 111(4):661-6. PubMed ID: 3513503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
    Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
    Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.
    Rothbart ST; Saksena S
    Am J Cardiol; 1986 Apr; 57(11):941-6. PubMed ID: 3515898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia.
    Mendes L; Podrid PJ; Fuchs T; Franklin S
    J Am Coll Cardiol; 1991 May; 17(6):1396-402. PubMed ID: 2016457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias.
    Foster MT; Peters RW; Froman D; Shorofsky SR; Gold MR
    Am J Cardiol; 1996 Jul; 78(1):47-50. PubMed ID: 8712117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.
    Au PK; Bhandari AK; Bream R; Schreck D; Siddiqi R; Rahimtoola SH
    J Am Coll Cardiol; 1987 Feb; 9(2):389-97. PubMed ID: 2433319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
    Dorian P; Newman D; Berman N; Hardy J; Mitchell J
    J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant metoprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible sustained monomorphic ventricular tachycardia.
    Brodsky MA; Chough SP; Allen BJ; Capparelli EV; Orlov MV; Caudillo G
    Am Heart J; 1992 Sep; 124(3):629-35. PubMed ID: 1514490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.